You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Boehringer Ingelheim
Express Scripts
Harvard Business School
Baxter

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,949,982

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,949,982 protect, and when does it expire?

Patent 9,949,982 protects FETROJA and is included in one NDA.

This patent has seven patent family members in five countries.

Summary for Patent: 9,949,982
Title:Preparation containing cephalosporin having a catechol moiety
Abstract: The present invention relates to a stable pharmaceutical composition comprising a compound represented by formula (I), its pharmaceutically acceptable salt or a solvate thereof. ##STR00001## The stable pharmaceutical composition can be prepared by comprising 1) a compound represented by formula (I), its pharmaceutically acceptable salt, or a solvate thereof, 2) one or more selected from the group consisting of alkali metal chlorides, alkaline earth metal chlorides, transition metal chlorides and magnesium chloride; and 3) sugar and/or a sugar alcohol.
Inventor(s): Kawasaki; Hidenori (Osaka, JP), Kojima; Natsuko (Osaka, JP), Fujihira; Atsushi (Osaka, JP), Takahashi; Kanako (Osaka, JP), Matsubara; Fumihiko (Osaka, JP), Matsuoka; Nao (Osaka, JP)
Assignee: Shionogi & Co., Ltd. (Osaka, JP)
Application Number:15/508,406
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 9,949,982

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc FETROJA cefiderocol sulfate tosylate POWDER;INTRAVENOUS 209445-001 Nov 14, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,949,982

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2014-180174Sep 4, 2014
PCT Information
PCT FiledSeptember 03, 2015PCT Application Number:PCT/JP2015/075040
PCT Publication Date:March 10, 2016PCT Publication Number: WO2016/035846

International Family Members for US Patent 9,949,982

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 106687116   Start Trial
European Patent Office 3189841   Start Trial
Japan 6218204   Start Trial
Japan WO2016035846   Start Trial
South Korea 101935186   Start Trial
South Korea 20170048511   Start Trial
World Intellectual Property Organization (WIPO) 2016035846   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Moodys
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.